, Volume 39, Issue 2, pp 190–197

Contribution of change in glycosylated haemoglobin to insulin-associated weight gain: results of a longitudinal study in type 2 diabetic patients

  • H. J. Jansen
  • J. C. Hendriks
  • B. E. de Galan
  • G. Penders
  • C. J. Tack
  • G. Vervoort
Original Article


To investigate the contribution of glycosylated haemoglobin change (HbA1c) on body weight in patients with type 2 diabetes after start of insulin therapy. We analysed 122 individual weight-profiles in relation to the change in HbA1c per se in these patients up to 36 months after the start of insulin therapy. Data were analysed separately for the first 9 months after commencement of insulin therapy and for the period thereafter. Within the first 9 months of insulin therapy mean body weight increased by 0.52 kg per month. HbA1c decreased from 9.9 ± 1.8 to 7.9 ± 1.3%. Only 12% of the initial weight gain could be attributed to the change in HbA1c. Furthermore, the mean monthly increase in body weight gain was reduced by 0.006 kg for every 1 kg higher body weight at baseline. From 9 to 36 months after start of insulin therapy, body weight increased by 0.1 kg/month, which was independent of change in HbA1c. Improvement of glycaemic control per se contributes little to initial weight gain after start of insulin therapy in patients with T2DM. After 9 months of insulin treatment, weight gain is unrelated to change in glycosylated haemoglobin. Other factors have to be responsible for weight gain after start of insulin therapy.


Weight gain Insulin therapy Type 2 diabetes mellitus 


  1. 1.
    R.C. Turner, C.A. Cull, V. Frighi, R.R. Holman, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281, 2005–2012 (1999)PubMedCrossRefGoogle Scholar
  2. 2.
    S. Makimattila, K. Nikkila, H. Yki-Jarvinen, Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 42, 406–412 (1999)PubMedCrossRefGoogle Scholar
  3. 3.
    M.E. Hickey, T.R. Hall, Insulin therapy and weight change in Native-American NIDDM patients. Diabetes Care 16, 364–368 (1993)PubMedCrossRefGoogle Scholar
  4. 4.
    J.Q. Purnell, J.E. Hokanson, S.M. Marcovina, M.W. Steffes, P.A. Cleary, J.D. Brunzell, Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 280, 140–146 (1998)PubMedCrossRefGoogle Scholar
  5. 5.
    D.A. McCarron, M.E. Reusser, Body weight and blood pressure regulation. Am. J. Clin. Nutr. 63, 423S–425S (1996)PubMedGoogle Scholar
  6. 6.
    S.E. Kahn, B. Zinman, S.M. Haffner et al., Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 55, 2357–2364 (2006)PubMedCrossRefGoogle Scholar
  7. 7.
    H. Yki-Jarvinen, L. Ryysy, M. Kauppila et al., Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82, 4037–4043 (1997)PubMedCrossRefGoogle Scholar
  8. 8.
    A. Salle, M. Ryan, G. Guilloteau, B. Bouhanick, G. Berrut, P. Ritz, ‘Glucose control-related’ and ‘non-glucose control-related’ effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients. Br. J. Nutr. 94, 931–937 (2005)PubMedCrossRefGoogle Scholar
  9. 9.
    S. Heller, Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 65(Suppl 1), S23–S27 (2004)PubMedCrossRefGoogle Scholar
  10. 10.
    A.N. Jacob, K. Salinas, B. ms-Huet, P. Raskin, Weight gain in type 2 diabetes mellitus. Diabetes Obes. Metab. 9, 386–393 (2007)PubMedCrossRefGoogle Scholar
  11. 11.
    R.R. Holman, K.I. Thorne, A.J. Farmer et al., Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J. Med. 357, 1716–1730 (2007)PubMedCrossRefGoogle Scholar
  12. 12.
    G. Verbeke, G. Molenberghs, Linear mixed models in practice: a SAS-oriented approach (Springer-Verlag, New York, 1997)Google Scholar
  13. 13.
    R.R. Holman, A.J. Farmer, M.J. Davies et al., Three-year efficacy of complex insulin regimens in type 2 diabetes. N. Engl. J. Med. 361, 1736–1747 (2009)PubMedCrossRefGoogle Scholar
  14. 14.
    D.S. Lasserson, P. Glasziou, R. Perera, R.R. Holman, A.J. Farmer, Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 52, 1990–2000 (2009)PubMedCrossRefGoogle Scholar
  15. 15.
    R.A. DeFronzo, Insulin and renal sodium handling: clinical implications. Int. J. Obes. 5(suppl 1), 93–104 (1981)PubMedGoogle Scholar
  16. 16.
    R.R. Wolfe, Effects of insulin on muscle tissue. Curr. Opin. Clin. Nutr. Metab. Care 3, 67–71 (2000)PubMedCrossRefGoogle Scholar
  17. 17.
    J. Rodin, J. Wack, E. Ferrannini, R.A. DeFronzo, Effect of insulin and glucose on feeding behavior. Metabolism 34, 826–831 (1985)PubMedCrossRefGoogle Scholar
  18. 18.
    R. Gougeon, M. Lamarche, J.F. Yale, T. Venuta, The prediction of resting energy expenditure in type 2 diabetes mellitus is improved by factoring for glycemia. Int. J. Obes. Relat. Metab. Disord. 26, 1547–1552 (2002)PubMedCrossRefGoogle Scholar
  19. 19.
    H.U. Janka, G. Plewe, M.C. Riddle, C. Kliebe-Frisch, M.A. Schweitzer, H. Yki-Jarvinen, Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28, 254–259 (2005)PubMedCrossRefGoogle Scholar
  20. 20.
    The DCCT Research Group, Weight gain associated with intensive therapy in the diabetes control, complications trial. Diabetes Care 11, 567–573 (1988)CrossRefGoogle Scholar
  21. 21.
    G. Biesenbach, A. Raml, N. Alsaraji, Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI. Diabetes Obes. Metab. 8, 669–673 (2006)PubMedCrossRefGoogle Scholar
  22. 22.
    UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment, risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • H. J. Jansen
    • 1
  • J. C. Hendriks
    • 2
  • B. E. de Galan
    • 1
  • G. Penders
    • 1
  • C. J. Tack
    • 1
  • G. Vervoort
    • 1
  1. 1.Department of General Internal Medicine 463Radboud University Nijmegen Medical CenterNijmegenThe Netherlands
  2. 2.Department of Biostatistics and EpidemiologyRadboud University Nijmegen Medical CenterNijmegenThe Netherlands

Personalised recommendations